Download presentation
Presentation is loading. Please wait.
Published byEzequiel Hulme Modified over 10 years ago
1
Multicenter database of clinical course of CKD patients Internal Medicine Jang Hye Ryoun
2
Chronic kidney disease Staging of CKD (chronic kidney disease) stage 1 ; GFR 90 mL/min stage 2 ; GFR 60~89 mL/min stage 3 ; GFR 30~59 mL/min stage 4 ; GFR 15~29 mL/min stage 5 ; GFR < 15 mL/min Inclusion criteria - CKD stage 2~5 - non-diabetic renal disease
3
CKD & cardiovascular risk CKD - independent risk factor of CVD Non-traditional risk factors - type of CKD- calcium and phosphorus - degree of GFR- oxidative stress - proteinuria- uremic toxins - inflammation- renin-angiotensin - malnutrition - anemia
4
Reversed epidemiology in ESRD patients A low (and not a high) total serum creatinine is associated with poor ESRD outcome (Lowrie, 1990) A low (and not a high) BMI or weight for height is associated with increased morbidity and mortality among ESRD patients (Kopple et al,1999; Fleischmann et al,1999) A low (and not a high) total serum cholesterol is associated with poor ESRD outcome (Lowrie, 1990) A low blood pressure may indicate poor outcome in ESRD (Zager, 1998) A low serum homocysteine may be associated with poor survival (Suliman et al, 2000; Wrone, 2001)
5
Causes of reversed epidemiology Survival bias (selection bias) Time discrepancy of competitive risk factors Impact of malnutrition
6
ACE gene Angiotensin-converting enzyme gene on chromosome 6 deletion allele (D) in the ACE gene increases serum and tissue ACE levels association with risk of progression of IgA nephropathy or chronic kidney disease DD genotype
7
Proposal Multicenter database of CKD clinical course Microarray detection of genes responsible for rapid renal function deterioration or cardiovascular disease
8
Methods Multicenter database of CKD clinical course - Treatment protocol - Database construction Microarray - in patients undergoing renal biopsy - searching for potentially responsible genes
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.